Regression of atherosclerosis through H3 and H4 acetylation; reduce mortality in acute HFpEF patients without coronary heart disease; prevent endothelial senescence via enhancing SIRT-1 expression; modulate eNOS expression in premature myocardial infarct patients; downregulate miR-146a/b in CAD patients; prevent ED by downregulating miR-221-5p, miR-27b-3p, and miR-16-2-3p. This evidence concerns the gene NOS3 and coronary artery disorder.